Methylgene and Pharmion announce collaboration to develop sirtuin inhibitors as anti-cancer agents

News | 08. 20. 2007

MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.